



**TOURO COLLEGE &  
UNIVERSITY SYSTEM**

**Touro Scholar**

Touro College of Osteopathic Medicine  
(Middletown) Publications and Research

Touro College of Osteopathic Medicine  
(Middletown)

2017

## Why Do Chemotherapeutic Drugs and Radiation Induce Cardiomyopathy and Cardiac Failure in Cancer Patients: Is This a Consequence of Unrecognized Hypomagnesemia and Release of Ceramides and Platelet-Activating Factor?

Burton M. Altura

Nilank C. Shah

*Touro College*, [nilank.shah@touro.edu](mailto:nilank.shah@touro.edu)

Gatha J. Shah

Bella T. Altura

Follow this and additional works at: [https://touro scholar.touro.edu/tcomm\\_pubs](https://touro scholar.touro.edu/tcomm_pubs)



Part of the [Cardiovascular Diseases Commons](#), and the [Neoplasms Commons](#)

### Recommended Citation

Altura, B. M., Shah, N. C., Shah, G. J., & Altura, B. T. (2017). Why Do Chemotherapeutic Drugs and Radiation Induce Cardiomyopathy and Cardiac Failure in Cancer Patients: Is This a Consequence of Unrecognized Hypomagnesemia and Release of Ceramides and Platelet-Activating Factor?. *SciFed Journal of Emergency Medicine*, 1 (1), [Article 1]. <https://doi.org/10.23959/sfjem-1000001>

This Article is brought to you for free and open access by the Touro College of Osteopathic Medicine (Middletown) at Touro Scholar. It has been accepted for inclusion in Touro College of Osteopathic Medicine (Middletown) Publications and Research by an authorized administrator of Touro Scholar. For more information, please contact Timothy J Valente [timothy.valente@touro.edu](mailto:timothy.valente@touro.edu).

# Why Do Chemotherapeutic Drugs and Radiation Induce Cardiomyopathy and Cardiac Failure in Cancer Patients: Is this a Consequence of Unrecognized Hypomagnesemia and Release of Ceramides and Platelet-Activating Factor?

\*<sup>1,5</sup>Burton M Altura, <sup>1,5</sup>Nilank C Shah, <sup>1</sup>Gatha J Shah, <sup>1,3,5</sup>Bella T Altura

<sup>1</sup>Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, Brooklyn, USA

<sup>2</sup>Department of Medicine, USA

<sup>3</sup>Center for Cardiovascular and Muscle Research, USA

<sup>4</sup>The School for Graduate Studies in Molecular and Cellular Science, State University of New York Downstate Medical Center, Brooklyn, USA

<sup>5</sup>Bio-Defense Systems, Inc, Rockville Centre, USA

## Ever since the earliest

use of platinum –based drugs having been given to cancer patients, there has been recognition of an increased incidence of cardiac failure and cardiomyopathy [ see 1-3]. Radiation- based therapy, either alone or more likely combined with chemotherapeutic drugs, has also been associated with cardiac failure and cardiomyopathy [4-11]. Although a patient may want to accept temporary occurrence of cardiac and cardiovascular dysfunctions of various types (e.g., QT prolongation, left ventricular dysfunctions, arrhythmias, fibrillations[ e.g., atrial fibrillation-AF], coronary ischemia, coronary vasospasm, pulmonary hypertension, myocardial infarctions, elevation in arterial blood pressure, congestive heart failure, venous and arterial thrombo-embolism, diastolic or systolic dysfunctions, coronary arterial inflammations, pericardial disease, and/or accelerated atherogenesis, etc.) for a higher potential of a cancer cure, the risk for cardiac failure or cardiomyopathy increases with dosing of many platinum-based chemotherapeutic drugs(PBCDs), aminoglycosides like amphotericin B as well as anthracyclines(e.g., doxorubicin), and antimetabolite agents like 5-fluorouracil [1-11]. It should be pointed out that many of these cardiovascular events occur after prolonged PCBDs , amphotericin B, anthracyclines, alkaloids(e.g., vinblastine), anti-tumor antibiotics(e.g., bleomycin) , cyclophosphamide or radiation treatment. Even treatment with a variety of the newer anti-angiogenic drugs such as the antibodies like bevacizumab, sorafenib, and sunitinib have been associated with cardio-and cardiovascular toxicities similar to the PBCDs, anthracyclines, amphotericin B and cyclophosphamide [4-11]. More recently, use of the small-molecule tyrosine kinase inhibitors, multiple

tyrosine kinase inhibitors, monoclonal antibodies to HERS2, as well as proteasome inhibitors (e.g., bortezomib, carfilzomib) have also been associated with increased incidences of cardio-toxicities [5-11]. Why, however, do these structurally, diverse chemotherapeutic drugs and radiation induce cardiac toxicity, unexplained coronary vasospasm, congestive heart failure, cardiomyopathy, and complete cardiac failure followed by death?

Almost four decades ago [13], two of us pointed out that there was a scattered number of clinical studies that were beginning to indicate that at least three of the chemotherapeutic drugs (i.e., cisplatin, vinbazine, and bleomycin) appeared to suggest that chemotherapeutic anticancer drugs may deplete the body of magnesium(Mg) [for references and review, see 1-3,12 ]. Ever since we suggested the potential danger of these drugs to the heart and cardiovascular system[13], a growing body of evidence has borne-out these initial dangers to cancer patients[e.g., for reviews see 4-11]. It appears from recent

\*Corresponding author: Burton M Altura, Department of Physiology and Pharmacology, State University of New York Downstate Medical Center, Brooklyn, USA. E-mail: baltura@downstate.edu

Received June 26, 2017; Accepted July 12, 2017; Published July 22, 2017

Citation: Burton M Altura (2017) Why Do Chemotherapeutic Drugs and Radiation Induce Cardiomyopathy and Cardiac Failure in Cancer Patients: Is this a Consequence of Unrecognized Hypomagnesemia and Release of Ceramides and Platelet-Activating Factor?. SF J Emer Med 1:1.

Copyright: © 2017 Burton M Altura. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

studies that cancer patients receiving cardiac transplants, who had taken chemotherapeutic drugs and/or radiation often showed unexplained, worsened depletion of Mg [for recent review, see 12]. How and why could depletion of body Mg stores, and Mg depletion from the heart and blood vessels, cause cardiac arrhythmias, elevated arterial blood pressure, prolonged QT intervals, coronary arterial vasospasm, myocardial ischemic events, myocardial infarctions, and sudden-cardiac death (SCD) ?

### **Relationship of Mg to Cardiac Stabilization and Function, Hypertension, Cardiomyopathy, and Sudden-Cardiac Death**

Over the past four decades, evidence has accumulated to indicate that daily dietary deficiency of Mg intake and/or errors in Mg metabolism pose serious risks for development of AF, hypertension, atherosclerosis, inflammation, endothelial cell dysfunctions, dysfunctions of cardiac bioenergetics, coronary arterial vasospasm, myocardial infarctions, coronary ischemic events, cardiomyopathy, cardiac failure, strokes and SCD[13-53], whereas higher than normal Mg intake is found to be associated with decreased or ameliorated AFs, myocardial infarctions, hypertension, strokes, and incidences of cardiomyopathies and SCD[16-33]. Moreover, there is a growing, scattered literature which suggests that cancer patients pretreated with Mg have less cardiotoxic events after chemo-or radiation treatment [2, 12]. Mg is a co-factor for more than 500 enzymes, and is the second most abundant intracellular cation after potassium and is a critical requirement for regulation of  $Ca^{2+}$ ,  $Na^+/K^+$  transport across all cell membranes [54]. It is vital in numerous physiological, cellular and biochemical reactions including carbohydrate, lipid, protein, DNA and RNA metabolism, membrane ion transport, among other pathways [19,22,27-33,36,37,42,46,49,51,52,54]. Several epidemiologic studies in North America and Europe have shown that people consuming Western-type diets are low in Mg content(i.e., 30-45 % of the RDA for Mg) [13,54-59]; most such studies in the USA show that 60-80% of Americans are consuming 185-235 mg/day of Mg [31,51,54-59]. In 1900, in contrast, most Americans were consuming 450-550 mg/day of Mg [31,51]. Low Mg content of drinking water, found in areas of soft-water and Mg-poor soil, is associated with high incidences of ischemic heart disease(IHD), atherosclerosis, coronary ischemia, hypertension, and SCD [13-17,21,28,31,51,55,56]. The myocardial level of Mg has consistently been observed to be lower in subjects

dying from IHD and SCD in soft-water areas than those subjects living in hard-water areas [14-17, 21,28,31,55, 56]. More than 45 years ago, two of us demonstrated that  $Mg^{2+}$  behaves as a natural calcium channel blocker in both cardiac and vascular smooth muscle (VSM) cells [19, 60-65]. We also showed that Mg behaves as a natural statin drug as it can lower cholesterol and triglyceride levels as well as act as a powerful vasodilator in the microcirculation, on coronary arteries and arterioles, and as cardiac muscle relaxant [16-19,23,27-33,36,48,50,66-68; unpublished findings]. Hypermagnesemic diets have been shown to ameliorate hypertension and atherogenesis as well as lower the incidences of arrhythmias and strokes [13, 20,28,31-33,44,49,51, 69-86].

### **Use of $Mg^{2+}$ Ion-Selective Electrodes in Diseased Patients**

Using sensitive and newly-designed specific  $Mg^{2+}$ -ion selective electrodes, our laboratories demonstrated that patients with hypertension, IHD, cardiac failure, ischemic and hemorrhagic strokes, blood loss, and atherogenesis exhibit significant reductions in plasma/serum/whole blood levels of ionized Mg [39, 40,51, 87-101]. Other experiments on cancer patients receiving a variety of the chemotherapeutic drugs mentioned, above, also demonstrate marked reductions in serum ionized Mg levels[for reviews, see 102]. We have shown that dietary deficiencies in Mg in rabbits and rats cause vascular remodeling(i.e., arteriolar wall hypertrophy and alterations in the matrices of the vascular walls) concomitant with atherogenesis, high blood pressure, and microvascular vessel vasospasm. Such events in cancer patients receiving the variety of chemotherapeutic drugs, discussed above, could easily account for cardiotoxic and cardiovascular disturbances seen with these drugs leading to cardiomyopathy, cardiac failure, and SCD.

### **Low $[Mg^{2+}]_0$ Environments Result in Concentration-dependent Coronary Arterial Vasospasm, Increased Vascular Reactivity to Endogenous Vasoconstrictor Agents, and Dysfunctions of Cardiac Hemodynamics**

Approximately 40 years ago, our group found that declining levels of extracellular  $Mg^{2+}$  ( $[Mg^{2+}]_0$ ) resulted in concentration-dependent constriction and vasospasm of small (<100  $\mu m$  in diameter), medium and large coronary arteries excised from dogs, sheep, baboons and rats. These

low  $[Mg^{2+}]_0$ -induced vasospasms could only be attenuated or inhibited with elevated concentrations of  $Mg^{2+}$ . In addition, we noted that low  $[Mg^{2+}]_0$  levels enhanced vasoconstrictor responses to a variety of vasoactive and neurohumoral transmitters (e.g., angiotensin II, serotonin, norepinephrine, multiple peptides, etc.). We suggested, at that time, that low dietary levels of Mg could result in arrhythmias, IHD and SCD. Ever since these early studies were published, a number of clinical studies have been published which support our hypothesis. Using perfused, working rat hearts, we found that low levels of  $Mg^{2+}$  result in reductions in coronary flows, reductions in cardiac output, reductions in stroke volume and peak systolic pressure development, reductions in myocardial intracellular  $Mg^{2+}$  levels, reduction in myocardial levels of ATP, increased levels of inorganic phosphate, acidification of atrial and ventricular myocytes,  $Ca^{2+}$  overload, and generation of powerful reactive oxygen and nitrogen species (e.g.,  $H_2O_2$ , hypochlorite ions, hydroxyl ions, ferrylmyoglobin, etc.). Taken together, such results, in themselves, could account for chemotherapeutic drug-induced AF, myocardial ischemia, coronary vasospasm, prolonged QT intervals, increased vascular tone and pressures, IHD, and SCD. But, added to these events are the multiple effects of low  $[Mg^{2+}]_0$  on intravessel inflammatory dynamics such as leukocytic, monocyte and platelet sticking to endothelial cell walls, increased postcapillary changes in vascular permeability, vasoconstriction in the coronary microcirculation, increased release of cytokines and chemokines, release of antibodies of diverse types, and release of complement proteins.

### **$Mg^{2+}$ Regulates Sphingolipid Pathways in Cardiac and Vascular Smooth Muscle Cells**

Recent studies, from our laboratories, indicate that  $Mg^{2+}$  can modulate sphingolipid pathways in both cardiac and vascular smooth muscle (VSM) cells. Ceramides are sphingolipids known to be released as a consequence of sphingomyelinases (SMases) acting on sphingomyelin (SM), a component of all extra- and intracellular cell membranes, or as a consequence of the activation of serine palmitoyl transferase 1 and 2 (SPT 1 and SPT 2) (a *de novo* synthetic pathway). Ceramides are now known to play important, and key, roles in fundamental pathophysiological processes such as inflammation, angiogenesis, atherogenesis, membrane-receptor functions, cell proliferation, microcirculatory functions,

cell adhesion, immunogenic responses, excitation-contraction coupling events in cardiac and VSM cells, and cell death (i.e., apoptosis). An upregulation of SPT 1 and SPT 2 has been hypothesized to play an important role in apoptosis cell death events taking place in atherogenesis. Such upregulation could be quite pivotal in producing plaques on the endothelium of coronary vessels leading to ischemic events, IHD, and SCD observed in cancer patients treated with diverse chemotherapeutic agents. Working with perfused rat hearts, we have noted incremental rises in ceramides as the  $[Mg^{2+}]_0$  was reduced concomitant with decreases in stroke volume, increased levels of lactic acid dehydrogenase and creatine phosphokinase, increased lipid peroxidation of cardiac muscle cells, reduction of cardiac intracellular pH, and generation of reactive-oxygen and nitrogen species. Preliminary experiments, with perfused hearts given increasing doses of doxorubicin yield very similar results [unpublished findings].

It is of considerable interest to note, here, that, experimentally, myocardial infarctions have recently been shown to be associated with rising levels of ceramides. In human subjects, it has been reported that stable angina pectoris, unstable angina pectoris, and acute myocardial infarction are also associated with rising levels of ceramides. In some of these patients, a clear elevation in SMases was observed along with a reduction in SM.

During the performance of our foregoing *in vitro* and *in vivo* low  $[Mg^{2+}]_0$  experiments, using proton-nuclear magnetic resonance spectroscopy, we noted a rapid formation of platelet-activating factor (PAF) and PAF-like lipid molecules.

### **$Mg^{2+}$ -Deficient Environments Lead to Formation of PAF and PAF-like Lipids: Potential Significance to Chemotherapeutic – induced Ischemic Cardiac Events**

PAF is now known to play major roles in inflammatory responses, blood pressure and atherogenesis. In addition, PAF and PAF-like lipids are known to affect the heart and cardiac muscle cells in numerous ways. For example, PAF can produce coronary arterial vasoconstriction, alter arterial blood pressure, increase coronary vascular resistance, release several lipid-like molecules from the heart, reduce cardiac output, decrease cardiac contractility, alter atrial and papillary muscle



chronotropicity and membrane action potentials, as well as alter potassium currents in isolated cardiomyocytes. All of these attributes of PAF's actions on the myocardium and the coronary vascular tree would be more than enough to cause profound atrial and ventricular fibrillation, and SCD. Moreover, a variety of the circulating blood-formed elements (e.g., polymorph nuclear leukocytes, platelets, basophils, and macrophages) can elaborate PAF and PAF-like lipids. Recently, we have reported that coronary, cerebral and aortic vSM cells as well as atrial and ventricular cardiac myocytes can also elaborate PAF, particularly when the diverse cells are exposed to low  $[Mg^{2+}]_0$  levels. A number of investigators employing intravital microscopy techniques, similar to those used in our laboratories have demonstrated that PAF increased the numbers of white blood cells in the microvessels concomitant with intense vasoconstriction-spasms with increasing concentrations of the putative lipid mediator (i.e., PAF), and less leukocyte rolling along the endothelial cell surfaces with increased venular-postcapillary permeability. Interestingly, we have found that ceramides can produce almost identical phenomena in a variety of microvascular beds, in vivo, when studied by high-resolution video microscopy. We believe rather firmly, that these older and newer experimental studies could be used to advance our hypothesis that generation and release of both PAF (and PAF-like lipids) and ceramides due, in large measure to chemotherapeutically- and diet-induced Mg-deficiency, are more than likely involved in generation of anti-cancer drug-induced cardiomyopathy, IHD, coronary vasospasm, and SCD.

### **Importance of Dietary Mg Supplementation for Prevention and Amelioration of Chemotherapeutic Anti-Cancer Drug –induced Cardiomyopathy, Cardiac Failure and SCD**

Over the past 30 years, our laboratories have been investigating the utility of using  $Mg^{2+}$  ion-selective electrodes and Mg-supplemented or naturally-occurring Mg-enriched spring waters to avoid the pitfalls of dietary- and/or metabolically-induced Mg-deficient states which affect heart health. Our results, to date, with the  $Mg^{2+}$ -electrodes (to accurately measure ionized Mg levels), bolster the idea that water intake (e.g., from tap waters, well waters, bottled waters, beverages using tap/well/spring waters, or distilled waters) in humans should contain at least 25–40 mg/liter/day of  $Mg^{2+}$ . A number of studies done in our labs indicate that most, if not all of

the cardiovascular manifestations (i.e., decreased cardiac output, decreased coronary flows, decreased myocardial contractility, lipid peroxidation of cardiac and coronary VSM cell membranes, synthesis/release of toxic ceramides, PAF, cytokines, and chemokines, as well as  $Ca^{2+}$  overload, myocardial acidification, loss of ATP, and apoptosis) observed in hearts of experimental animals fed low dietary Mg intake, can either be prevented or greatly ameliorated when the animals imbibe drinking waters with appropriate amounts of  $Mg^{2+}$ . We are convinced the latter inclusion in our diets and those of all cancer patients should go a long-way towards the prevention and amelioration of atrial and ventricular arrhythmias, decreased cardiac output and contractility, increased coronary vascular resistance, hypertension, and cardiac ischemic events leading to IHD and SCD. In this context, it is of particular interest to note that several clinical studies have shown some positive effects of Mg therapy (either prophylactic or orally administered) in several types of cancer patients treated with PBCDs.

### **Conclusions**

Although the exact cause(s) of PBCD-induced cardiomyopathy, cardiac failure and SCD in cancer patients is not known,  $Mg^{2+}$ -depletion is clearly observed in many of these treated subjects. Experimentally, low dietary intake of Mg or animals given PBCDs demonstrate most, if not all, of the pathophysiological cardiovascular effects observed in cancer patients given these antitumor drugs. Generation/ release of ceramides and PAF, as well as PAF-like lipids, appear to be critically-involved in the cardiovascular effects of Mg-deficiency and most likely in PBCD-induced cardiac manifestations in patients. In view of our data, and hypothesis, it would probably be prudent to undertake clinical trials to determine if antagonists of SMases, SPT 1 and SPT 2, as well as antagonists of PAF would, along with Mg supplementation, reduce markedly the incidence and severity of cardiac problems in patients treated with PBCDs.

### **Acknowledgements**

The authors acknowledge that many of our clinical and experimental studies, over five decades, were supported, in part, by Research Grants from The N.I.H. to B.M.A. and B.T.A. These included grants from The National Heart Lung, and Blood Institute; The national Institute on Drug Abuse; The National Institute on Alcoholism and Alcohol Abuse; and The National Institute on Mental Health. In

addition, a number of pharmaceutical companies provided unrestricted grants for some of our studies.

## Reference

1. Edwards GS, Lane M, Smith FE et al. (1979) long-term treatment with cis-dichlorodiammine platinum (II) –vinblastine-bleomycin possible association with severe coronary artery disease. *Cancer Treatm Rep* 63: 551-552.
2. Schilsky RL, Anderson T (1979) Hypomagnesemia and renal magnesium wasting in patients receiving cisplatin. *Ann Intern Med* 90: 929-931.
3. Volgelzang NJ, Bosi GJ, Johnson K, et al. (1981) Raynaud's phenomenon a common toxicity after combination therapy for testicular cancer. *An Intern Med* 95: 288-292.
4. Goldberg MA, Antin JH, Guinan EC, et al. (1986) Cyclophosphamide cardiotoxicity An analysis of dosing as a risk factor. *Blood* 66(5): 1114-1118.
5. Khakoo AY, Yeh ETH (2008) Therapy insight: management of cardiovascular disease in patients with cancer and cardiac complications of cancer therapy. *Nature Clin Practice Oncol* 5: 655-667.
6. Eschenhagen T, Force T, Ewer MS, et al. (2011) cardiovascular side effects of cancer therapies a position statement from the Heart Failure Association of the European Society of Cardiology. *Eur J heart Failure* 13: 1-10.
7. Oliveira GH, Hardawy BW, Kucheryavaya AY, et al. (2102) Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. *J Heart Lung Transpl* 31: 805-810.
8. Crigliano G, Cardinale D, Suter T, et al. (2012) Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy ESMO clinical practice guidelines. *Ann Oncol* 23(suppl 7) vii155-vii 166.
9. Aleman BMP, Moser EC, Nuver J, et al. (2014) Cardiovascular disease after cancer therapy. *EJC Cancer Suppl* 12: 18-28.
10. Moslehi JJ (2016) Cardiovascular toxic effects of targeted cancer therapies. *N Engl J Med* 375: 1457-1465.
11. Kenigsberg B, Campia U, Barac A et al. (2016) Cardiovascular side effects of cancer treatments. *The Pharmaceutical J*.
12. Green J , Valero M, Perkowski L et al. (2015) Identifying and treating magnesium deficiency in cancer patients receiving platinum based chemotherapy. *Natural Med J* 7.
13. Altura BM, Altura BT (1985) New perspectives on the role of magnesium in the pathophysiology of the cardiovascular system. I Clinical aspects *Magnesium* 4: 226-244.
14. Crawford T, Crawford MD (1967) Prevalence and pathological changes of ischemic heart disease in a hard-water and in a soft-water area. *Lancet* 1: 229-232.
15. Anderson TW, Le Riche WH, McKay JS et al. (1969) Sudden death and ischemic heart disease Correlation with hardness of local water supply. *N Engl J Med* 280: 805-807.
16. Altura BM (1979) Sudden-death ischemic heart disease and dietary magnesium intake is the target site coronary vascular smooth muscle. *Med Hypotheses* 5: 843-848.
17. Turlapaty PDMV, Altura BM (1980) Magnesium deficiency produces spasms of coronary arteries relationship to etiology of sudden death ischemic heart disease. *Science* 208: 198-200.
18. Altura BM, Altura BT, Carella A et al. (1981) Hypomagnesemia and vasoconstriction possible relationship to etiology of sudden death ischemic heart disease and hypertensive vascular disease. *Artery* 9: 212-231.
19. Altura BM, Altura BT (1981) Magnesium ions and contraction of vascular smooth muscles Relationship to some vascular diseases. *Federation Proc* 40: 2672-2679.
20. Altura BM, Altura BT, Gebrewold A, et al. (1984) Magnesium deficiency and hypertension: correlation between magnesium deficiency diets and microcirculatory changes in situ. *Science* 223: 1325-1317.
21. Leary WP (1986) Content of magnesium in drinking water and deaths from ischaemic heart disease in white South Africans. *Magnesium* 5: 150-153.
22. Rayssiguier Y, Gueux E (1986) Magnesium and lipids in cardiovascular disease. *J Am Coll Nutr* 5: 507-519.
23. Friedman HS, Nguyen TN, Mokraoui AM, et al. (1987) Effects of magnesium chloride on cardiovascular hemodynamics in the neutrally intact dog. *J Pharmacol Exp Ther* 243: 126-130.
24. Rasmussen HS, Cinton C, McNair P, et al. (1987) Magnesium deficiency in patients with increased heart disease, with and without myocardial infarction, uncovered by an intravenous loading test In *Proceedings of Trace Elements in Human Health and Disease, Second Nordic Symposium, Odense. WHO, Geneva* 16-20.
25. Kimura T, Yasue H, Sakaino N, et al. (1989) Effects of

- magnesium on the tone of isolated human coronary arteries. *Circulation* 79: 1118-1124.
26. Goto K, Yasue H, Okumura K (1990) Magnesium deficiency detected by intravenous loading test in variant angina pectoris. *Am J Cardiol* 65: 709-712.
27. Altura BT, Brust M, Bloom S, et al. (1990) Magnesium deficiency modulates blood lipid levels and atherogenesis. *Proc Nat Acad Sci USA* 87: 1840-1844.
28. Altura BM, Altura BT (1990) Magnesium and the cardiovascular system experimental and clinical aspects. *Meals in Biological Systems* 26: 359-416.
29. Eisenberg MJ (1992) Magnesium deficiency and sudden death. *Am heart J* 124: 544-549.
30. Altura BM, Zhang A, Altura BT (1993) Magnesium, hypertensive vascular disease atherogenesis, subcellular compartmentation of  $Ca^{2+}$  and  $Mg^{2+}$  and vascular contraction. *Mineral Electrolyte Metab* 19: 323-336.
31. Altura BM, Altura BT (1995) Magnesium and cardiovascular risk factors and atherogenesis. *Cell Mol Biol Res* 41: 347-359.
32. Altura BM, Altura BT (1995) Magnesium in cardiovascular biolog. *Sci Am Sci Med* 2: 28-37.
33. Altura BM, Altura BT (1995) Magnesium and cardiovascular diseases In *Handbook on Metal-Ligand Interactions in Biological Fluids*. Berthon G, ed. Marcel Dekker Inc New York p 822-842.
34. Fogh-Anderen N, Altura BM, Altura BT, et al. (1995) Composition of interstitial fluid. *Clin Chem* 41: 522-525.
35. Satake K, Lee JD, Shinizu H, et al. (1996) Relation between severity of magnesium deficiency and frequency of angina attacks in men with variant angina. *J Am Coll Cardiol* 28: 897-902.
36. Altura BM, Gebrewold A, Altura BT, et al. (1996) Magnesium depletion impairs carbohydrate and lipid metabolism and cardiac bioenergetics and raises myocardial calcium content in vivo relationships to etiology of cardiac diseases. *Biochem Molecular Biol Int* 40: 1183-1190.
37. Delpiano M, Altura BM (1996) Modulatory effect of extracellular  $Mg^{2+}$  ions on  $K^+$  and  $Ca^{2+}$  currents of capillary endothelial cells from rat brain. *FEBS Lett* 394: 335-339.
38. Altura BT, Memon ZI, Zhang A, et al. (1997) Low levels of serum ionized magnesium found in patients early after stroke which results in rapid elevation in cytosolic free calcium and spasm in cerebral vascular smooth muscle cells. *Neurosci Lett* 230: 37-40.
39. Resnick LM, Bardicef D, Altura BT, et al. (1997) Serum ionized magnesium Relation to blood pressure and racial factors. *Am J Hypertens* 10: 1420-1424.
40. Altura BM, Zhang A, Altura BT (1997) Exposure of piglet coronary arterial cells to low concentrations of  $Mg^{2+}$  found in blood of ischemic heart disease patients result in rapid elevation of cytosolic  $Ca^{2+}$  relevance to sudden infant death syndrome. *Eur J Pharmacol* 338: R7-R9.
41. Delpiano M, Altura BM (1997) Transmembrane currents in capillary endothelial cells are modulated by  $Mg^{2+}$  ions. *Adv Exp Mol Biol* 410: 115-118.
42. Morrill GA, Gupta RK, Kostellow AB, et al. (1997)  $Mg^{2+}$  modulates membrane lipids in vascular smooth muscle link to atherogenesis. *FEBS Lett* 408: 191-194.
43. Liao F, Folsom AR, Brancati FL (1998) Is low magnesium concentration a risk factor for coronary heart disease The Atherosclerosis risk in Communities (ARIC) Study. *Am Heart J* 136:480-490.
44. Rubenowitz E, Molin I, Axelsson G, et al. (2000) Magnesium in drinking water in relation to morbidity and mortality from acute myocardial infarction. *Epidemiology* 11: 416-421.
45. Peacock JM, Ohira T, Post W, et al. (2010) Serum magnesium and risk of sudden death in the Atherosclerosis Risk in Communities (ARIC) Study. *Am Heart J* 160(3): 464-470.
46. Emila S, Swaminathan S (2013) Role of magnesium in health and disease. *J Exp Sci* 4(2): 32-43.
47. Malpeuch-Brugere C, Nowacki W, Daveaux M, et al. (2000) Inflammatory response following acute magnesium deficiency in the rat. *Biochim Biophys Acta* 1501: 91-98.
48. Yang ZW, Li W, Wang J, et al. (2000)  $Mg^{2+}$  -induced endothelial -dependent relaxation of blood vessels and blood pressure lowering: role of NO. *Am J Physiol Regulatory Interg Comp Physiol* 278: R628-R639.
49. Touyz RM (2003) Role of magnesium in the pathogenesis of hypertension. *Mol Aspects Med* 24: 107-136.
-

50. Altura BM, Barbour RL, Dowd TL, et al. (2003) Low extracellular magnesium depletion induces intracellular free Mg<sup>2+</sup> deficits, ischemia depletion of high-energy phosphates and cardiac failure in intact working hearts a 31P-NMR study. *Biochim Biophys Acta* 1182: 329-332.
51. Altura BM, Altura BT (2007) Magnesium : forgotten mineral in cardiovascular biology and angiogenesis In *New Perspectives in Magnesium Research*, Nishizawa N, Morii H, Durlach J, eds. Springer London UK.
52. Shah NC, Liu JP, Iqbal J, et al. (2011) Mg deficiency results in modulation of serum lipids glutathione and NO synthase isozyme activation in cardiovascular tissues relevance to de novo synthesis of ceramide serum Mg and atherogenesis. *Int J Clin Exp Med* 4: 103-118.
53. Weglicki WB (2012) Hypomagnesemia and inflammation clinical and basic aspects. *Annu Rev Nutr* 32: 55-71.
54. de Baaij JHF, Hoenderop JG, Bindels RJ (2015) Magnesium in man Implications for health and disease. *Physiol Rev* 95: 1-46.
55. Marier JH (1982) Quantitative factors regarding magnesium status in the modern-day world. *Magnesium* 1: 3-15.
56. Marier JH, Neri LC (1985) Quantifying the role of magnesium in the interrelationship between human mortality/morbidity and water hardness. *Magnesium* 4: 53-59.
57. Ford ES, Mokdad AH (2003) Dietary magnesium intake in a national sample of US adults. *J Nutr* 133: 2879-2882.
58. D, La Comb R (2009) What We Eat in America NHANES 2005-2006 usual Nutrient Intakes from Food and Water Compared to 1997 Dietary Reference Intakes for Vitamin D Calcium Phosphorus and Magnesium US Department of Agricultural Research Washington DC.
59. Altura BM, Altura BT et al. (2016) Importance of ionized magnesium measurements in physiology and medicine and the need for ion-selective electrodes. *J Clin Case Studies* 1.
60. Altura BM, Altura BT et al. (1971) Influence of magnesium on drug-induced contractions and ion content in rabbit aorta. *Am J Physiol* 220: 939-944.
61. Altura BM, Altura BT et al. (1974) Magnesium and contraction of arterial smooth muscle. *Microvasc Res* 7: 5-16.
62. Altura BM, Altura BT et al. (1978) Magnesium and vascular tone and reactivity. *Blood Vessels* 13: 5-15.
63. Altura BM, Altura BT (1981) Role of magnesium ions in contractility of blood vessels and skeletal muscle. *Magnesium Bulletin* 2:102-114.
64. Altura BM, Altura BT (1981) General anesthetics and magnesium ions as calcium antagonists In *New Perspectives on Calcium Antagonists*. Am Physiol Soc Bethesda 131-145.
65. Altura BM, Altura BT (1981) Magnesium modulates calcium entry and contractility in vascular smooth muscle In *The Mechanism of Gated Calcium Transport Across Biological Membranes*. Academic Press. New York 137-145.
66. Nagai I, Gebrewold A, Altura BT, et al. (1988) Magnesium salts exert direct vasodilator effects on rat cremaster muscle microcirculation. *Arch Intern Pharmacodyn Ther* 294: 194-214.
67. Nishio A, Gebrewold A, Altura BT, et al. (1988) Comparative effects of magnesium salts on reactivity of arterioles and venules to constrictor agents An in situ study on microcirculation. *J Pharmacol Exp Ther* 246: 859-865.
68. Nishio A, Gebrewold A, Altura BT, et al. (1989) Comparative vasodilator effects of magnesium salts on rat mesenteric arterioles and venules. *Arch Int Pharmacodyn Ther* 298: 139-165.
69. Dyckner T, Wester PO (1979) Effect of magnesium on blood pressure. *Br Med J* 286: 1847-1849.
70. Seelig MS (1980) Magnesium Deficiency in the Pathogenesis of Disease Plenum Press. New York.
71. Mortin BC, Smith FM, McKibbin TG (1981) Magnesium therapy in acute myocardial infarction. *Magnesium Bulletin* 3: 192-194.
72. Altura BM, Ising H (1981) Magnesium and Health. *Artery* 9: 166-252.
73. Iseri LT, Chung P, Tobis J (1983) Magnesium therapy for intractable ventricular tachyarrhythmias in normomagnesemic patients. *West J Med* 138: 823-828.
74. Altura BT, Altura BM (1984) The role of magnesium in etiology of strokes and cerebrovasospasm. *Magnesium* 1: 277-291.
75. Altura BT, Altura BM (1984) Interactions of Mg and K on cerebral blood vessels Aspects in view of stroke: review of present status and findings. *Magnesium* 3: 195-211.
76. Altura BM, Altura BT (1984) Interactions of Mg and K on



---

blood vessels-aspects in view of hypertension Review of present status and new findings. *Magnesium* 3: 175-194.

77. Cohen L, Kitzes R (1984) Magnesium sulfate in the treatment of variant angina *Magnesium* 3: 46-49.

78. Durlach J (1985) *Le Magnesium Practique Clinique* . Bailliere Paris.

79. Altura BM, Altura BT (1986) Biochemistry and pathophysiology of congestive heart failure Is there a role for magnesium? *Magnesium* 5: 134-143.

80. Altura BT, Altura BM (1987) Cardiovascular actions of magnesium: Importance in etiology and treatment of high blood pressure. *Magnesium Bulletin* 9: 6-21.

81. Altura BM (1988) Ischemic heart disease and magnesium. *Magnesium* 7:57-67.

82. Altura BM, Altura BT, Gebrewold A, et al. (1992) Noise-induced hypertension and magnesium: relationship to microcirculation and calcium. *J Appl Physiol* 72: 194-202.

83. Altura BM, Altura BT (1992) Cardiovascular risk factors and magnesium relationships to atherosclerosis ischemic heart disease and hypertension. *Magn Trace Elem* 10: 182-192.

84. Altura BM, Altura BT (1995) Role of magnesium in the pathogenesis of hypertension updated: relationship to its actions on cardiac, vascular smooth muscle, and endothelial cells. In: *Hypertension: Pathophysiology Diagnosis and Management* Laragh JH, Brenner BM, eds, 2nd edn. Raven Press, New York 1213-1242.

85. Altura BM, Altura BT (1997) Mg and atherogenesis. In *Magnesium Current Status and New Developments* Theophanides T, Anastassopoulou I. Kluwer-Academic Publ, New York 385-396.

86. Gruber U, Schmidt J, Kisters K (2015) Magnesium in prevention and therapy. *Nutrients* 7: 8199-8226.

87. Altura BT, Altura BM (1991) Measurement of ionized magnesium in whole blood, plasma and serum with a new ion-selective electrode in healthy and diseased human subjects. *Magnesium Trace Elem* 10: 90-98.

88. Altura BT, Shirey TL, Young CC, Dell'Orfano K, et al. (1992) A new method for the rapid determination of ionized Mg<sup>2+</sup> in whole blood, serum and plasma. *Methods Find Exp Clin Pharmacol* 14: 297-304.

89. Altura BT, Shirey TL, Young CC, et al. (1992) Characterization and studies of a new ion selective electrode for free extracellular magnesium ions in whole blood, plasma and serum. In: D'Orazio P, Buritt M, Sena SF (eds) *Electrolytes, Blood Gases, and Other Critical Analytes The Patient, the Measurement, and the Government*. Omni Press, Madison 152-173.

90. Handwerker SM, Altura BT, Royo B, et al. (1993) Ionized magnesium and calcium levels in umbilical cord serum of pregnant women with transient hypertension during labor. *Am J Hypertens* 6: 542-545.

91. Markell MS, Altura BT, Barbour RL, et al. (1993) ionized and total magnesium levels in cyclosporine-treated renal transplant recipients: relationship with cholesterol and cyclosporine levels. *Clin Sci* 85: 315-318.

92. Resnick LM, Altura BT, Gupta RK, et al. (1993) Intracellular and extracellular magnesium depletion in type 2 (non-insulin-dependent) diabetes mellitus. *Diabetologia* 36: 767-770.

93. Fogh-Andersen N , Altura BM, Altura BT, et al. (1995) Composition of interstitial fluid. *Clin Chem* 41: 1522-1525.

94. Scott VL, DeWolf AM, Kang Y, Altura BT, Virji MA, et al. (1996) Ionized hypomagnesemia in patients undergoing orthotopic liver transplantation a complication of citrate intoxication. *Liver Transpl Surg* 2: 343-347.

95. Altura BM, Altura BT (1996) Role of magnesium in pathophysiological processes and the clinical utility of magnesium ion selective electrodes. *Scand J Clin Lab invest* 224: 211-234.

96. Fogh-Andersen N, Altura BM, Altura BT, et al. (1996) Changes in plasma ionized calcium and magnesium in blood donors after donation of 450 ml blood Effects of hemodilution and Donnan equilibrium. *Scand J Clin Lab Invest* 56(suppl 224): 245-250.

97. Seelig MS, Altura BM (1997) How best to determine magnesium requirements Need to consider cardiotherapeutic drugs that affect its retention. *J Am Coll Nutr* 16: 4-6.

98. Sinert R, Zehtabchi S, Desai S, Peacock P, Altura BT, et al. (2007) Serum ionized magnesium and calcium levels in adult patients with seizures. *Scand J Clin Lab Invest* 67: 317-326.

99. Apostol A, Apostol R, Ali E, Choi A, Ehsuni N, et al. (2009) Cerebral spinal fluid and serum ionized magnesium and calcium levels in preeclamptic women during administration of

**Citation:** Burton M Altura (2017) Why Do Chemotherapeutic Drugs and Radiation Induce Cardiomyopathy and Cardiac Failure in Cancer Patients: Is this a Consequence of Unrecognized Hypomagnesemia and Release of Ceramides and Platelet-Activating Factor?. SF J Emer Med1:1.

---

magnesium sulfate. Fert Steril 94: 276-282.

100. Altura BM, Li W, Zhang A, Zheng T, Shah NC, et al. (2016) Sudden cardiac death in infants, children and young adults possible roles of dietary magnesium intake and generation of platelet-activating factor in coronary arteries. J Heart Health 2.

101. Altura BM, Shah NC, Shah GJ, et al. (2016) Why is Postoperative atrial fibrillation difficult to prevent and treat potential roles of unrecognized magnesium deficiency and release of ceramide and platelet-activating factor. Int J Surg Res 3: 47-51.

102. Altura BM, Lewenstam A (1994) Unique magnesium ion-selective electrodes. Scan J Clin Lab Invest 54: 1-100.

**Citation:** Burton M Altura (2017) Why Do Chemotherapeutic Drugs and Radiation Induce Cardiomyopathy and Cardiac Failure in Cancer Patients: Is this a Consequence of Unrecognized Hypomagnesemia and Release of Ceramides and Platelet-Activating Factor?. SF J Emer Med1:1.